Apollo, Max Healthcare Rose After Centre's Cancer Drug Trade Margin Cap
Hospital and healthcare counters saw significant buying traction during Friday's trading session on Dalal Street, with frontliners like Max Healthcare Institute and Apollo Hospitals Enterprise posting sharp intraday advances. Midcap healthcare operators including Fortis Healthcare, Krishna Institute of Medical Sciences (KIMS), and Yatharth Hospital followed suit, registering gains between 3% and 4.2%. Investor enthusiasm surged following the central government's formal move to rationalize trade margins on essential non-scheduled anti-cancer medications, ending widespread market ambiguity over potential pricing intervention.
Why Investors Cheered the 30% Trade Margin Cap Over Court Recommendations
The primary catalyst lifting hospital equities was relief over the regulatory threshold chosen by policy makers. The central government decided to cap the trade margin on all non-scheduled anti-cancer formulations at 30% of the Maximum Retail Price (MRP). This move provided immediate respite to hospital management desks and institutional investors who had feared far more restrictive curbs following recent Supreme Court proceedings. On September 29, a bench comprising Justices Vikram Nath and Sandeep Mehta had flagged aggressive markups—citing instances where medicines supplied at ₹2,700 carried retail tags of ₹27,000—and advocated for a uniform 16% margin ceiling. The government's decision to settle on a 30% cap preserves sustainable pharmacy dispensing margins for institutional hospital networks while still delivering patient relief.
NPPA Move to Slash Cancer Drug Costs by Up to 70%
Under the framework managed by the National Pharmaceutical Pricing Authority (NPPA), the trade margin rationalization targets 110 identified oncology formulations, including 35 high-cost patented therapies, with the final notification scheduled to take effect later this month. Market analysis conducted by the pricing regulator revealed historical markups on non-scheduled oncology drugs averaging 170%, with specific critical life-saving molecules climbing past 700% along various supply chain intermediaries. By capping retail markups, the central government projects a net retail price decline ranging from 20% to 70% across key oncology brands, creating an estimated annual out-of-pocket saving of nearly ₹2,500 crore for cancer patients across India without disrupting institutional distribution networks.
